MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Improvement in upper limb spasticity patterns in the elderly following treatment with incobotulinumtoxinA: a pooled analysis

M. Munin, A. Camões-Barbosa, C. Cordero-García, M. Althaus, G. Comes, M. Vacchelli, C. Walter, J. Wissel (Pittsburgh, USA)

Meeting: 2024 International Congress

Abstract Number: 1524

Keywords: Botulinum toxin: Clinical applications: spasticity, Spasticity: Treatment, Xeomin

Category: Spasticity

Objective: To compare changes from baseline in upper limb spasticity (ULS) severity in different spastic patterns at 4 weeks and 12 weeks post-injection of incobotulinumtoxinA (incoA) versus placebo (PBO) in a large sample of elderly patients.

Background: Elderly patients are underrepresented in clinical trials due to inclusion and exclusion criteria. Data from clinical trials of botulinum toxin in ULS are therefore scarce in this patient population.

Method: Data from seven prospective, multicentre studies of incoA in the treatment of upper or upper and lower limb muscle spasticity in adults from across the world and with a range of ethnicities were pooled. In all studies, adult patients could receive incoA at a total body dose of 400 U. This analysis focuses on patients aged ≥65 years with ULS manifesting as a variety of spastic patterns; the least squares mean (LSM) change from baseline differences between incoA and PBO in Ashworth Scale (AS) score at 4- and 12-weeks post injection were calculated (one of the pooled studies used modified AS scores). “As observed” data were analyzed using ANCOVA. Safety was also evaluated throughout the 12-week period.

Results: Mean (SD) age of the 267 included patients was 70.3 (4.2) years; 15.0% were aged ≥75 years, 62.6% were male and mean (SD) time from spasticity diagnosis was 5.0 (5.4) years. The aetiology of spasticity was stroke in >99% of patients. For all ULS patterns with sufficient power for statistical analysis, incoA produced greater improvement in AS score compared with PBO at week 4 (p<0.05); for most of these patterns, the difference remained significant at week 12 (p<0.05) (Fig.1). IncoA was generally well tolerated, with no treatment-related serious adverse events or deaths reported (Table 1).

Conclusion: Results of this analysis in a large group of elderly patients from around the world show that incoA was well tolerated and upper limb muscle tone was improved. Therefore, ULS predominantly due to stroke was reduced.

Table 1.

Table 1.

Fig. 1

Fig. 1

To cite this abstract in AMA style:

M. Munin, A. Camões-Barbosa, C. Cordero-García, M. Althaus, G. Comes, M. Vacchelli, C. Walter, J. Wissel. Improvement in upper limb spasticity patterns in the elderly following treatment with incobotulinumtoxinA: a pooled analysis [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/improvement-in-upper-limb-spasticity-patterns-in-the-elderly-following-treatment-with-incobotulinumtoxina-a-pooled-analysis/. Accessed July 6, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/improvement-in-upper-limb-spasticity-patterns-in-the-elderly-following-treatment-with-incobotulinumtoxina-a-pooled-analysis/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley